Imugene (FRA:ILA) Change In Payables And Accrued Expense : €0.00 Mil (TTM As of Dec. 2023)

View and export this data going back to 2024. Start your Free Trial

What is Imugene Change In Payables And Accrued Expense?

Imugene's Change In Payables And Accrued Expense for the quarter that ended in Dec. 2023 was €0.00 Mil. It means Imugene's Accounts Payable & Accrued Expense stayed the same from Jun. 2023 to Dec. 2023 .

Imugene's Change In Payables And Accrued Expense for the fiscal year that ended in Jun. 2024 was €0.00 Mil. It means Imugene's Accounts Payable & Accrued Expense stayed the same from Jun. 2023 to Jun. 2024 .

Imugene Change In Payables And Accrued Expense Historical Data

The historical data trend for Imugene's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Imugene Change In Payables And Accrued Expense Chart

Imugene Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Change In Payables And Accrued Expense

Get a 7-Day Free Trial

Imugene Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Change In Payables And Accrued Expense	Get a 7-Day Free Trial															-	-	-	-	-

Imugene Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.00 Mil.

Imugene Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of Imugene's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Imugene Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Imugene Ltd (FRA:ILA) » Definitions » Change In Payables And Accrued Expense

Comparable Companies

Traded in Other Exchanges

IUGNF:USA IMU:Australia

Address

4-6 Bligh Street, Suite 12.01, Level 12, Sydney, NSW, AUS, 2000

Website

https://www.imugene.com

Imugene Ltd specializes in a clinical-stage immuno-oncology company. Its products include HER-Vaxx, PD1-Vaxx, CF33 and CF33 CD19. HER-Vaxx is a proprietary HER2 +ve cancer vaccine that stimulates a polyclonal antibody response to HER2/neu. The company is also developing B-cell peptide cancer vaccines and therapeutics. Its only operating segment is the Research and Development of oncolytic immunotherapies.

Imugene Headlines

No Headlines